16373716 |
Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala
McLean, SR,
Boshoff, C,
Hartzoulakis, B,
Gana-Weisz, M,
Frow, R,
Whelan, J,
Selwood, D
|
Mol. Cancer Ther. |
2005 |
15363456 |
Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase
Griffith, R,
Foster, R,
Ferrao, P,
Ashman, L
|
J. Mol. Graph. Model. |
2004 |
22089421 |
Gastrointestinal stromal tumours: origin and molecular oncology
Barnett, CM,
Corless, CL,
Heinrich, MC
|
Nat. Rev. Cancer |
2011 |
25239608 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
Anjum, R,
Heinrich, MC,
Ketzer, J,
Bauer, S,
Zhu, M,
Zhou, T,
Serrano, C,
Song, Y,
Fletcher, JA,
Schrock, A,
Ning, Y,
Eilers, G,
Wardwell, S,
Gozgit, JM,
Kohlmann, A,
Garner, AP,
Rivera, VM,
Vodala, S,
Clackson, T,
Wang, F
|
Clin. Cancer Res. |
2014 |
29704617 |
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
Roskoski, R
|
Pharmacol. Res. |
2018 |
12481435 |
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
Frost, MJ,
Ferrao, PT,
Hughes, TP,
Ashman, LK
|
Mol. Cancer Ther. |
2002 |
30792533 |
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Heinrich, MC,
Ketzer, J,
Bauer, S,
Zhu, M,
Presnell, A,
Raut, CP,
George, S,
Mannan, AM,
Serrano, C,
Yu, C,
Sicinska, E,
Tao, DL,
Rubin, BP,
Fletcher, JA,
Mariño-Enríquez, A,
Demetri, GD,
Eilers, G,
Czaplinski, JT,
McKinley, A
|
Br. J. Cancer |
2019 |
15342366 |
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
Raymond, AK,
Choi, H,
Frazier, ML,
Wu, EF,
Feig, BW,
Hittelman, W,
Ramdas, L,
Velasco, MA,
Patel, S,
Oyedeji, CO,
Pollock, RE,
Prieto, VG,
Benjamin, RS,
Zhang, W,
Burgess, MA,
Hayes, KJ,
Trent, JC,
Chen, LL,
Macapinlac, HA,
Hunt, KK,
Fuller, GN
|
Cancer Res. |
2004 |
16751810 |
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
Greco, A,
Carbone, A,
Ferrone, M,
Pilotti, S,
Casali, PG,
Negri, T,
Fermeglia, M,
Lagonigro, MS,
Gronchi, A,
Pricl, S,
Miselli, F,
Tamborini, E,
Pierotti, MA
|
Oncogene |
2006 |
28478525 |
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
Morales-Barrera, R,
Carles, J,
Suárez, C,
García-Valverde, A,
Olivares, D,
Valverde, C,
George, S,
Serrano, C
|
Target Oncol |
2017 |
17363509 |
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Griffith, R,
Odell, AF,
Roberts, KG,
Baleato, RM,
Lyons, AB,
Ashman, LK,
Byrnes, EM
|
Mol. Cancer Ther. |
2007 |
19164557 |
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Quenzer, T,
Emmett, MR,
Deshmukh, GD,
Lunney, EA,
English, JM,
Wu, JC,
Christensen, J,
Molina, D,
He, YA,
Zhang, Y,
Greig, MJ,
Demetri, GD,
Yu, X,
Diehl, W,
McTigue, M,
Gajiwala, KS,
DiNitto, JP,
Wells, PA,
Jacques, SL,
Zou, A,
Zhang, HM,
Marshall, AG
|
Proc. Natl. Acad. Sci. U.S.A. |
2009 |
29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Heinrich, MC,
Kent, JD,
Klug, LR
|
Pharmacol. Ther. |
2018 |
30792534 |
Secondary KIT mutations: the GIST of drug resistance and sensitivity
Napolitano, A,
Vincenzi, B
|
Br. J. Cancer |
2019 |